Last 12 months
Inside the activity.
0 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2019 Filed Jan 26, 2019 01:21 UTC |
SILVERNAIL LAUREN PSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001570562-19-000024 · wf-form4_154846567750670.xml · derivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 20:20 UTC |
BLANK SIMONEDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001570562-19-000022 · wf-form4_154846560188517.xml · derivative · entry 1 BLANK SIMONE · CIK 0001366840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 23, 2019 Filed Jan 26, 2019 01:22 UTC |
Jafar Michael M.Chief Marketing Officer
|
GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001570562-19-000025 · wf-form4_154846571498976.xml · derivative · entry 1 Jafar Michael M. · CIK 0001744242 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 23, 2019 Filed Jan 26, 2019 01:20 UTC |
MOATAZEDI DAVIDDirector · See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001570562-19-000023 · wf-form4_154846563955209.xml · derivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 23, 2019 Filed Jan 26, 2019 01:19 UTC |
Hau BosunDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001570562-19-000021 · wf-form4_154846556396551.xml · derivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 23, 2019 Filed Jan 26, 2019 01:18 UTC |
Romine KristineDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001570562-19-000020 · wf-form4_154846552009207.xml · derivative · entry 1 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 23, 2019 Filed Jan 26, 2019 01:17 UTC |
Malik VikramDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001570562-19-000017 · wf-form4_154846540438935.xml · derivative · entry 1 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 02:52 UTC |
Romine KristineDirector
|
PurchaseCommon Stock | 5,000 | $12.75 | $63,750.00 |
DisclosureSEC source: 0001570562-18-000131 · wf-form4_154510151046328.xml · nonDerivative · entry 2 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,347 Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 02:50 UTC |
Malik VikramDirector
|
PurchaseCommon Stock | 7,800 | $13.04 | $101,688.60 |
DisclosureSEC source: 0001570562-18-000129 · wf-form4_154510144090151.xml · nonDerivative · entry 1 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 F1 · price: The shares were purchased in multiple trades at prices ranging from $12.92 to $13.07. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 21:51 UTC |
GILL DAVID NDirector
|
PurchaseCommon Stock | 3,000 | $12.77 | $38,300.10 |
DisclosureSEC source: 0001570562-18-000130 · wf-form4_154510147610889.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · price: The shares were purchased in multiple trades at prices ranging from $12.72 to $12.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 02:52 UTC |
Romine KristineDirector
|
PurchaseCommon Stock | 11,000 | $12.50 | $137,453.80 |
DisclosureSEC source: 0001570562-18-000131 · wf-form4_154510151046328.xml · nonDerivative · entry 1 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,347 F1 · price: The shares were purchased in multiple trades at prices ranging from $12.35 to $12.70. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:07 UTC |
AEON Biopharma, Inc.10% owner
|
SaleCommon Stock | 573,888 | $14.00 | $8,034,432.00 |
DisclosureSEC source: 0001078782-18-001389 · primary_doc.xml · nonDerivative · entry 1 Alphaeon Corp · CIK 0001622667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,268,987 Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 16:27 UTC |
BLANK SIMONEDirector
|
PurchaseCommon Stock | 295,024 | $14.00 | $4,130,336.00 |
DisclosureSEC source: 0001570562-18-000125 · wf-form4_154387242681208.xml · nonDerivative · entry 1 BLANK SIMONE · CIK 0001366840 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 295,024 F1 · price: The acquisition of the shares of common stock referenced in this Form 4 was conducted in a private transaction between ALPHAEON Corporation ("ALPHAEON") and Dental Innovations BVBA ("DI"). DI holds certain notes issued by ALPHAEON. DI elected to receive payment from ALPHAEON of the outstanding principal amounts of the notes due on December 23, 2018 in the form of shares of common stock rather than cash. The shares of common stock received by the Dental Innovations BVBA are deemed "restricted securities" under Rule 144 promulgated under the Securities Act of 1933, as amended. F2 · ownership.nature: The reported securities are directly owned by DI and may be deemed beneficially owned by the Reporting Person as a shareholder of DI. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:27 UTC |
Romine KristineDirector
|
PurchaseCommon Stock | 6,347 | $14.00 | $88,858.00 |
DisclosureSEC source: 0001570562-18-000124 · wf-form4_154387240503332.xml · nonDerivative · entry 1 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,347 F1 · price: The acquisition of the shares of common stock referenced in this Form 4 was conducted in a private transaction between ALPHAEON Corporation ("ALPHAEON") and the Reporting Person. The Reporting Person holds certain notes issued by ALPHAEON. The Reporting Person elected to receive payment from ALPHAEON of the outstanding principal amounts of the notes due on December 23, 2018 in the form of shares of common stock rather than cash. The shares of common stock received by the Reporting Person are deemed "restricted securities" under Rule 144 promulgated under the Securities Act of 1933, as amended. Read SEC document |
| September 14, 2018 Filed Sep 19, 2018 01:18 UTC |
Jafar Michael M.Chief Marketing Officer
|
PurchaseCommon Stock | 12,800 | $20.83 | $266,590.72 |
DisclosureSEC source: 0001570562-18-000110 · wf-form4_153731987653084.xml · nonDerivative · entry 1 Jafar Michael M. · CIK 0001744242 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 16:31 UTC |
AEON Biopharma, Inc.10% owner
|
SaleCommon Stock | 1,750,000 | $21.04 | $36,820,000.00 |
DisclosureSEC source: 0001078782-18-000975 · primary_doc.xml · nonDerivative · entry 1 Alphaeon Corp · CIK 0001622667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,842,875 Read SEC document |
| August 22, 2018 Filed Aug 29, 2018 01:29 UTC |
Romine KristineDirector
|
GrantCommon Stock | 160 | $19.98 | $3,196.80 |
DisclosureSEC source: 0001570562-18-000104 · wf-form4_153550613550322.xml · nonDerivative · entry 2 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 1,360 F2 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose Read SEC document |
| August 22, 2018 Filed Aug 29, 2018 01:29 UTC |
Romine KristineDirector
|
PurchaseCommon Stock | 10,000 | $19.83 | $198,270.00 |
DisclosureSEC source: 0001570562-18-000104 · wf-form4_153550613550322.xml · nonDerivative · entry 1 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · price: The shares were purchased in multiple trades at prices ranging from $19.70 to $19.93. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:01 UTC |
AEON Biopharma, Inc.10% owner
|
SaleCommon Stock | 1,000,000 | $18.80 | $18,800,000.00 |
DisclosureSEC source: 0001570562-18-000094 · wf-form4_153237608581846.xml · nonDerivative · entry 1 Alphaeon Corp · CIK 0001622667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,592,875 F1 · kind: The Reporting Persons sold shares to the underwriters in connection with the closing of the Issuer's follow-on public offering. The reported sale price reflects the price at which the Reporting Persons sold shares to the underwriters, which is net of underwriting commissions. Read SEC document |
| June 18, 2018 Filed Jun 21, 2018 00:44 UTC |
Jafar Michael M.Chief Marketing Officer
|
GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $28.32 | $0.00 |
DisclosureSEC source: 0001570562-18-000066 · wf-form4_152954187337225.xml · derivative · entry 2 Jafar Michael M. · CIK 0001744242 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2028-06-18 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of June 18, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| June 18, 2018 Filed Jun 21, 2018 00:44 UTC |
Jafar Michael M.Chief Marketing Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-18-000066 · wf-form4_152954187337225.xml · nonDerivative · entry 1 Jafar Michael M. · CIK 0001744242 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,200 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of June 18, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 20:27 UTC |
Malik VikramDirector
|
PurchaseCommon Stock | 8,600 | $28.88 | $248,353.38 |
DisclosureSEC source: 0001570562-18-000057 · wf-form4_152909443160111.xml · nonDerivative · entry 1 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,600 F1 · price: The shares were purchased in multiple trades at prices ranging from $28.83 to $28.8993. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 21:49 UTC |
Romine KristineDirector
|
PurchaseCommon Stock | 2,000 | $28.05 | $56,100.00 |
DisclosureSEC source: 0001570562-18-000055 · wf-form4_152849455074302.xml · nonDerivative · entry 2 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 21:49 UTC |
Romine KristineDirector
|
PurchaseCommon Stock | 200 | $33.40 | $6,680.00 |
DisclosureSEC source: 0001570562-18-000055 · wf-form4_152849455074302.xml · nonDerivative · entry 1 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 1,200 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose F2 · balance_after: Due to an inadvertent error, the number of shares owned by the Reporting Person's Son was overstated on a Form 4 filed on June 4, 2018 by 1,000 shares. The previous error has been corrected in the current filing. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:18 UTC |
Hau BosunDirector
|
PurchaseCommon Stock | 2,898 | $34.94 | $101,255.83 |
DisclosureSEC source: 0001570562-18-000053 · wf-form4_152848912138903.xml · nonDerivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,040 F1 · price: The shares were purchased in multiple trades at prices ranging from $34.8064 to $35.1064. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 21:08 UTC |
Hau BosunDirector
|
PurchaseCommon Stock | 7,142 | $29.19 | $208,471.41 |
DisclosureSEC source: 0001570562-18-000051 · wf-form4_152823283258474.xml · nonDerivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,142 F1 · price: The shares were purchased in multiple trades at prices ranging from $28.93 to $29.3899. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:18 UTC |
Romine KristineDirector
|
PurchaseCommon Stock | 4,000 | $25.74 | $102,948.00 |
DisclosureSEC source: 0001570562-18-000049 · wf-form4_152814342858962.xml · nonDerivative · entry 3 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F2 · price: The shares were purchased in multiple trades at prices ranging from $25.324 to $26.15. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:18 UTC |
Romine KristineDirector
|
PurchaseCommon Stock | 1,000 | $24.40 | $24,400.00 |
DisclosureSEC source: 0001570562-18-000049 · wf-form4_152814342858962.xml · nonDerivative · entry 2 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 2,000 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:18 UTC |
Romine KristineDirector
|
PurchaseCommon Stock | 2,000 | $24.40 | $48,800.00 |
DisclosureSEC source: 0001570562-18-000049 · wf-form4_152814342858962.xml · nonDerivative · entry 1 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| May 29, 2018 Filed May 31, 2018 20:15 UTC |
SILVERNAIL LAUREN PSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $22.44 | $0.00 |
DisclosureSEC source: 0001570562-18-000044 · wf-form4_152779767553759.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-05-29 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 29, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| May 29, 2018 Filed May 31, 2018 20:15 UTC |
SILVERNAIL LAUREN PSee Remarks
|
GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-18-000044 · wf-form4_152779767553759.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 29, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| May 06, 2018 Filed May 9, 2018 01:19 UTC |
MOATAZEDI DAVIDDirector · See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 1,182,019 | $7.28 Strike: $7.28 | $8,605,098.32 |
DisclosureSEC source: 0001570562-18-000029 · wf-form4_152582874753746.xml · derivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,182,019 Underlying: Common Stock · 1,182,019 shares Expires 2028-05-06 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 6, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 13:36 UTC |
GILL DAVID NDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,696 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001570562-18-000021 · wf-form4_152476415212778.xml · derivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,696 Underlying: Common Stock · 22,696 shares Expires 2028-04-24 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of February 12, 2018. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 13:37 UTC |
HAYMAN ROBERTDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,086 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001570562-18-000023 · wf-form4_152476422333797.xml · derivative · entry 1 HAYMAN ROBERT · CIK 0001269349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,086 Underlying: Common Stock · 9,086 shares Expires 2028-04-24 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of January 6, 2018. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 13:35 UTC |
BLANK SIMONEDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,086 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001570562-18-000020 · wf-form4_152476413598851.xml · derivative · entry 1 BLANK SIMONE · CIK 0001366840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,086 Underlying: Common Stock · 9,086 shares Expires 2028-04-24 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of January 6, 2018. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 17:37 UTC |
Romine KristineDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,086 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001570562-18-000025 · wf-form4_152476425529423.xml · derivative · entry 1 Romine Kristine · CIK 0001730037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,086 Underlying: Common Stock · 9,086 shares Expires 2028-04-24 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of January 6, 2018. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 17:37 UTC |
Malik VikramDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,086 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001570562-18-000024 · wf-form4_152476423933800.xml · derivative · entry 1 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,086 Underlying: Common Stock · 9,086 shares Expires 2028-04-24 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of January 6, 2018. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 17:37 UTC |
Hau BosunDirector
|
GrantStock Option (Right to Buy) · Derivative | 9,086 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001570562-18-000022 · wf-form4_152476420693760.xml · derivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,086 Underlying: Common Stock · 9,086 shares Expires 2028-04-24 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of January 6, 2018. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 01:08 UTC |
AEON Biopharma, Inc.10% owner
|
ConversionSeries A Preferred Stock · Derivative | 1,250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-18-001613 · wf-form4_151857049936322.xml · derivative · entry 2 Alphaeon Corp · CIK 0001622667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,065,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Effective immediately upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series A preferred stock automatically converted into 1.6527 shares of the Issuer's common stock. The Series A preferred stock had no expiration date. F2 · derivative.exercise_date: Effective immediately upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series A preferred stock automatically converted into 1.6527 shares of the Issuer's common stock. The Series A preferred stock had no expiration date. F2 · derivative.expiration_date: Effective immediately upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series A preferred stock automatically converted into 1.6527 shares of the Issuer's common stock. The Series A preferred stock had no expiration date. F1 · derivative.underlying_shares: Reflects a 1.6527-for-1 forward stock split of the Issuer's common stock effected on January 26, 2018. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 01:08 UTC |
AEON Biopharma, Inc.10% owner
|
ConversionCommon Stock | 2,065,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-001613 · wf-form4_151857049936322.xml · nonDerivative · entry 1 Alphaeon Corp · CIK 0001622667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,065,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects a 1.6527-for-1 forward stock split of the Issuer's common stock effected on January 26, 2018. F2 · price: Effective immediately upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series A preferred stock automatically converted into 1.6527 shares of the Issuer's common stock. The Series A preferred stock had no expiration date. F1 · balance_after: Reflects a 1.6527-for-1 forward stock split of the Issuer's common stock effected on January 26, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.